335 related articles for article (PubMed ID: 23976960)
1. Clinical trial to evaluate the safety and immunogenicity of a trivalent surface antigen seasonal influenza vaccine produced in mammalian cell culture and administered to young and elderly adults with and without A(H1N1) pre-vaccination.
Loebermann M; Voss U; Meyer S; Bosse D; Fritzsche C; Klammt S; Frimmel S; Riebold D; Reisinger EC
PLoS One; 2013; 8(8):e70866. PubMed ID: 23976960
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu®): an open label, uncontrolled study.
Vinnemeier CD; Fischer-Herr J; Meyer S; Liebig K; Theeß W; Burchard GD; Cramer JP
Hum Vaccin Immunother; 2014; 10(2):441-8. PubMed ID: 24240428
[TBL] [Abstract][Full Text] [Related]
3. A 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine--Assessing the immunogenicity and safety in an open label, uncontrolled study.
Roggelin L; Vinnemeier CD; Meyer S; Witte K; Marx L; Theeß W; Burchard GD; Rolling T; Cramer JP
Hum Vaccin Immunother; 2015; 11(10):2370-5. PubMed ID: 26114800
[TBL] [Abstract][Full Text] [Related]
4. A phase III, open-label, single-arm, study to evaluate the safety and immunogenicity of a trivalent, surface antigen inactivated subunit influenza virus vaccine produced in mammalian cell culture (Optaflu®) in healthy adults.
Loebermann M; Fritzsche C; Geerdes-Fenge H; Heijnen E; Kirby D; Reisinger EC
Infection; 2019 Feb; 47(1):105-109. PubMed ID: 30298473
[TBL] [Abstract][Full Text] [Related]
5. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
6. Safety, immunogenicity and cross-reactivity of a Northern hemisphere 2013-2014 seasonal trivalent inactivated split influenza virus vaccine, Anflu®.
Shen Y; Hu Y; Meng F; Du W; Li W; Song Y; Ji X; Huo L; Fu Z; Yin W
Hum Vaccin Immunother; 2016 May; 12(5):1229-34. PubMed ID: 26934750
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a seasonal trivalent inactivated split influenza vaccine: a phase I randomized clinical trial in healthy Serbian adults.
Stevanovic G; Lavadinovic L; Filipovic Vignjevic S; Holt R; Ilic K; Berlanda Scorza F; Sparrow E; Stoiljkovic V; Torelli G; Madenwald T; Socquet M; Barac A; Ilieva-Borisova Y; Pelemis M; Flores J
Hum Vaccin Immunother; 2018 Mar; 14(3):579-586. PubMed ID: 29239682
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186
[TBL] [Abstract][Full Text] [Related]
9. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.
Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Stukova M; Buzitskaya Z; Кulmagambetov I; Davlyatshin T; Khairullin B
Hum Vaccin Immunother; 2018 Mar; 14(3):609-614. PubMed ID: 29112488
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the immunogenicity and safety of the conventional subunit, MF59-adjuvanted, and intradermal influenza vaccines in the elderly.
Seo YB; Choi WS; Lee J; Song JY; Cheong HJ; Kim WJ
Clin Vaccine Immunol; 2014 Jul; 21(7):989-96. PubMed ID: 24828092
[TBL] [Abstract][Full Text] [Related]
12. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
[TBL] [Abstract][Full Text] [Related]
13. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
Front Immunol; 2018; 9():2465. PubMed ID: 30405641
[No Abstract] [Full Text] [Related]
14. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
15. Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients.
Ott U; Sauerbrei A; Lange J; Schäfler A; Walther M; Wolf G; Wutzler P; Zell R; Krumbholz A
Med Microbiol Immunol; 2012 Aug; 201(3):297-302. PubMed ID: 22350187
[TBL] [Abstract][Full Text] [Related]
16. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
[TBL] [Abstract][Full Text] [Related]
17. The safety and immunogenicity of trivalent inactivated influenza vaccination: a study of maternal-cord blood pairs in Taiwan.
Lin SY; Wu ET; Lin CH; Shyu MK; Lee CN
PLoS One; 2013; 8(6):e62983. PubMed ID: 23762229
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study.
Loebermann M; Anders G; Brestrich G; Fritzsche C; Klammt S; Boršo D; Frimmel S; Riebold D; Reisinger EC
Vaccine; 2011 Feb; 29(6):1228-34. PubMed ID: 21167116
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Safety of Trivalent Split Influenza Vaccine in Healthy Korean Adults with Low Pre-Existing Antibody Levels: An Open Phase I Trial.
Kang K; Han S; Hong T; Jeon S; Paek J; Kang JH; Yim DS
Yonsei Med J; 2016 Nov; 57(6):1354-60. PubMed ID: 27593862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]